This finding prompted us to test the effect of cell cycle inhibitors, namely gefitinib, an inhibitor of epidermal growth factor receptor (EGFR), and rapamycin, an inhibitor of mTOR, on AD. Here, EGFR is linked to Alzheimer disease.